Sulfur mustard, a potent chemical warfare vesicant, is considered to be a high priority chemical threat.? Although it has been studied for more than 80 years, the mechanisms mediating its actions as a vesicant? remain unknown; moreover, to date, there are no effective medical countermeasures for exposure to warfare? vesicants. The proposed UMDNJ/Rutgers University CounterACT Research Center of Excellence will? specifically focus on the development of drugs to treat sulfur mustard poisoning. In collaborative studies with? a local pharmaceutical company and Battelle Memorial Institute, we have identified two candidate classes of? Pharmaceuticals that can prevent or reverse sulfur mustard toxicity. At least one member of each class of? drugs has previously been approved by the FDA for other indications. In this academic/industrial? partnership, plans are to optimize the lead compounds from the groups we have identified, to determine the? active pharmacophores, and ultimately to synthesize structural isomers. We will also evaluate the efficacy of? these potential countermeasures in model systems of sulfur mustard toxicity. In addition, Research and? Development Projects are proposed that are designed to identify specific mechanisms of action of sulfur? mustard and potential new targets for therapeutic intervention in three major vesicant targets: the eye, the? skin and the lung. Investigators on these projects will work closely with a Pharmacology and Drug? Development Core and a Medicinal Chemistry and Pharmaceutics Core with considerable expertise in drug? development, providing insights to facilitate the development of sulfur mustard countermeasures. The? research laboratories of the PI, co-Pi, Pi's of the Research and Development Projects, the Pharmaceutics? group and Pharmacology and Drug Development Core are located in close proximity to one another on the? Busch campus of Rutgers University. They are all members of the Environmental and Occupational Health? Sciences Institute (EOHSI), a facility jointly sponsored by UMDNJ-Robert Wood Johnson Medical School? and the School of Pharmacy at Rutgers University. EOHSI has been designated as an NIEHS Center of? Excellence. The Medicinal Chemistry group is located at Lehigh University, approximately 25 miles from? Rutgers University. The P.I. of this Center (J. Laskin) and the P.I. of the Medicinal Chemistry Core (N.? Heindel) have been jointly funded by NIEHS on drug development grants for over 15 years. A Training and? Education Program is proposed that will be directed at health care providers at Rutgers University School of? Pharmacy, UMDNJ-School of Public Health, UMDNJ-Robert Wood Johnson Medical School and the Health? Sciences Program at Lehigh University.?

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54AR055073-01
Application #
7224427
Study Section
Special Emphasis Panel (ZNS1-SRB-R (23))
Program Officer
Baker, Carl
Project Start
2006-09-28
Project End
2011-05-31
Budget Start
2006-09-28
Budget End
2007-05-31
Support Year
1
Fiscal Year
2006
Total Cost
$3,806,951
Indirect Cost
Name
University of Medicine & Dentistry of NJ
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Moretti, Alysha; Li, Qi; Chmielowski, Rebecca et al. (2018) Nanotherapeutics Containing Lithocholic Acid-Based Amphiphilic Scorpion-Like Macromolecules Reduce In Vitro Inflammation in Macrophages: Implications for Atherosclerosis. Nanomaterials (Basel) 8:
Szilagyi, John T; Fussell, Karma C; Wang, Yun et al. (2018) Quinone and nitrofurantoin redox cycling by recombinant cytochrome b5 reductase. Toxicol Appl Pharmacol 359:102-107
Joseph, Laurie B; Composto, Gabriella M; Perez, Roberto M et al. (2018) Sulfur mustard induced mast cell degranulation in mouse skin is inhibited by a novel anti-inflammatory and anticholinergic bifunctional prodrug. Toxicol Lett 293:77-81
Chang, Yoke-Chen; Gordon, Marion K; Gerecke, Donald R (2018) Expression of Laminin 332 in Vesicant Skin Injury and Wound Repair. Clin Dermatol (Wilmington) 2:
Venosa, Alessandro; Gow, James G; Hall, LeRoy et al. (2017) Regulation of Nitrogen Mustard-Induced Lung Macrophage Activation by Valproic Acid, a Histone Deacetylase Inhibitor. Toxicol Sci 157:222-234
Francis, Mary; Sun, Richard; Cervelli, Jessica A et al. (2017) Editor's Highlight: Role of Spleen-Derived Macrophages in Ozone-Induced Lung Inflammation and Injury. Toxicol Sci 155:182-195
Chmielowski, Rebecca A; Abdelhamid, Dalia S; Faig, Jonathan J et al. (2017) Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation. Acta Biomater 57:85-94
Francis, Mary; Groves, Angela M; Sun, Richard et al. (2017) Editor's Highlight: CCR2 Regulates Inflammatory Cell Accumulation in the Lung and Tissue Injury following Ozone Exposure. Toxicol Sci 155:474-484
Malaviya, Rama; Laskin, Jeffrey D; Laskin, Debra L (2017) Anti-TNF? therapy in inflammatory lung diseases. Pharmacol Ther 180:90-98
Faig, Jonathan J; Moretti, Alysha; Joseph, Laurie B et al. (2017) Biodegradable Kojic Acid-Based Polymers: Controlled Delivery of Bioactives for Melanogenesis Inhibition. Biomacromolecules 18:363-373

Showing the most recent 10 out of 145 publications